Method to treat lung cancer
One example embodiment relates to a method of treating lung cancer by administering a compound of formula I to a subject in need thereof. Another embodiment relates to a method to treat Non-Small Cell Lung Cancer (NSCLC) by administering the compound of formula I to a patient.
1. A method of treating lung cancer in a subject in need thereof, comprising:
administering a therapeutically effective amount of a compound to the subject to treat the lung cancer,
wherein the compound is presented by formula I
2. The method of claim 1 , wherein the lung cancer is Non-Small Cell Lung Cancer (NSCLC).
3. The method of claim 1 , wherein tumors of the lung cancer include epidermal growth factor receptor (EGFR) mutations.
4. The method of claim 1 , wherein tumors of the lung cancer include L858R mutant EGFR.
5. The method of claim 1 , wherein tumors of the lung cancer include T790M mutant EGFR.
6. The method of claim 1 , wherein tumors of the lung cancer include L858R and T790M mutant EGFR.
7. The method of claim 1 , wherein tumors of the lung cancer are resistant to Gefitinib.
8. The method of claim 1 , wherein the compound activates 5′-adenosine monophosphate-activated protein kinase (AMPK) to treat the lung cancer.
9. The method of claim 2 , wherein tumors of the NSCLC include epidermal growth factor receptor (EGFR) mutations.
10. The method of claim 2 , wherein tumors of the NSCLC include L858R mutant EGFR.
11. The method of claim 2 , wherein tumors of the NSCLC include T790M mutant EGFR.
12. The method of claim 2 , wherein tumors of the NSCLC include L858R and T790M mutant EGFR.
13. The method of claim 2 , wherein tumors of the NSCLC develop resistance to Gefitinib.
14. The method of claim 2 , wherein the compound activates 5′-adenosine monophosphate-activated protein kinase (AMPK) to treat the NSCLC.